MyoKardia to Present at Two Upcoming Investor Conferences in November
Oct 31, 2016 12:01 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2016 -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases,...
MyoKardia to Present at Two Upcoming Investor Conferences in November
Oct 31, 2016 12:01 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2016 -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases,...
FibroGen Completes Enrollment in Roxadustat Phase 3 Studies in China
Oct 31, 2016 12:01 pm UTC| Business
SAN FRANCISCO, Oct. 31, 2016 -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company, today reported completion of enrollment in its Phase 3 clinical trials in China for roxadustat (FG-4592) in...
FibroGen Completes Enrollment in Roxadustat Phase 3 Studies in China
Oct 31, 2016 12:01 pm UTC| Business
SAN FRANCISCO, Oct. 31, 2016 -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company, today reported completion of enrollment in its Phase 3 clinical trials in China for roxadustat (FG-4592) in...
Vericel to Host Third-Quarter 2016 Earnings Webcast and Conference Call on November 7, 2016
Oct 31, 2016 12:01 pm UTC| Business
CAMBRIDGE, Mass., Oct. 31, 2016 -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following...
Vericel to Host Third-Quarter 2016 Earnings Webcast and Conference Call on November 7, 2016
Oct 31, 2016 12:01 pm UTC| Business
CAMBRIDGE, Mass., Oct. 31, 2016 -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following...
Oct 31, 2016 12:01 pm UTC| Business
3rd Quarter vs. 2ndQuarter 2016 Highlights: Earnings of $34.7 million, or $0.25 per common shareLoan growth of 4.1% annualizedTangible book value1 increase of 2.4%Stable Core Net Interest Margin1Decline in Noninterest...